= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Denver

MSACL 2018 EU Abstract

Topic: Metabolomics

Podium Presentation in the Ether on Thursday at 9:40 (Chair: Éva Hunyadi-Gulyás)

Profiling Pathways of Estrogen Metabolism in Patients with Pulmonary Arterial Hypertension: Development of a Novel Assay for Estrogen Metabolites by LC-MS/MS

Nina Denver (Presenter)
University of Glasgow

Presenter Bio(s): Nina Denver is a PhD Student working within the lab of Professor Mandy MacLean at the University of Glasgow collaborating with the mass spectrometry core lead by Professor Ruth Andrew at the Queen’s Medical Research Institute, University of Edinburgh. Her research focus is on the role of estrogen and its metabolites in the onset and progression of pulmonary arterial hypertension (PAH). Prior to this, she obtained an international Erasmus mundus master degree in chemistry from Paris Sud University, Paris, France and Adam Mickiewicz University, Poznan, Poland and received her undergraduate degree from Glasgow Caledonian University with first class honours in Forensic Investigation.

Authors: Nina Denver1, Ruth Andrew2, Natalie ZM Homer2, Shazia Khan2, Colin Church3, Margaret R MacLean1.
(1) Institute of Cardiovascular and Medical Sciences, University of Glasgow, G12 8QQ. (2) Mass Spectrometry Core, Queen’s Medical Research Facility, University of Edinburgh, EH16 4TJ (3) Golden Jubilee Hospital, Agamemnon St, Clydebank, Glasgow, G81 4DY


Pulmonary arterial hypertension (PAH) is a debilitating, life limiting, commonly misdiagnosed disease, which ultimately leads to right heart failure and death. Estrogen metabolism plays a key role in disease onset and progression. To simultaneously quantify circulating estrogen levels in human plasma a sensitive liquid chromatography mass spectrometry (LC-MS/MS) was developed to compare plasma from healthy controls and PAH patients. Initial studies show increases in metabolites involved in PAH pathophysiology prompting further investigation for potential diagnostic and therapeutic strategies. Furthermore, implementation of this method will be clinically relevant to a number of estrogen sensitive diseases.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: